Enlaza Therapeutics, the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (“Vertex”) (Nasdaq: VRTX) to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small-format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.
Lei Wang is the lead UCSF inventor.